Complete List of Monoclonal antibody (PD-L1 inhibitor) Medicines
Brand: TECENTRIQ |
Strength: 1200 mg |
Form: Concentrate For Solution For Infusion
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and ...
Brand: TECENTRIQ |
Strength: 1875 mg/1 vial |
Form: Solution For Injection
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and ...
Brand: TECENTRIQ |
Strength: 840 mg |
Form: Powder for Concentrate for Solution for Infusion.
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer, and other m...
Brand: TECENTRIQ |
Strength: 840 mg |
Form: Powder for Concentrate for Solution for Infusion.
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and ...
Brand: BAVENCIO |
Strength: 20 mg/ml |
Form: Concentrate For Dilution For Infusion
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of metastatic Merkel cell carcinoma (MCC) in adults and pediatric patients, and treatment of locally advanced or metastatic urothelial...
Brand: IMFINZI |
Strength: 50 mg/ml |
Form: Solution For Injection
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of unresectable stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following platinum-based che...
Brand: IMFINZI |
Strength: 50 mg/ml |
Form: Solution For Injection
Class: | Monoclonal antibody (PD-L1 inhibitor)
Use: | Treatment of unresectable stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following platinum-based che...